Bioequivalence study of a fixed dose combination of nitazoxanide and ofloxacin in Indian healthy volunteers

被引:0
|
作者
Agarwal, Sangita [1 ]
Solomon, W. D. Sam [1 ]
Gowda, K. Veeran [1 ]
Selvan, P. Senthamil [1 ]
Ghosh, Debotri [1 ]
Sarkar, Amlan Kand [1 ]
Chattaraj, Tapas Kumar [1 ]
Pal, Tapan Kumar [1 ]
机构
[1] Jadavpur Univ, Bioequivalence Study Ctr, Dept Pharmaceut Technol, Kolkata 700032, W Bengal, India
来源
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH | 2007年 / 57卷 / 10期
关键词
antibiotics; antiparasitic drugs; CAS; 55981-09-4; 82419-36-1; nitazoxanide; active metabolite; bioavailability; bioequivalence; fixed dose combination; ofloxacin;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Objective. The pharmacokinetics of nitazoxanide (CAS 55981-09-4) and ofloxacin (CAS 82419-36-1) has been extensively evaluated in adult human volunteers individually after oral administration of tablet formulation. However, no published data is available regarding the combined pharmacokinetics and bioavailability of this particular fixed dose combination. In light of the above, a clinical study was designed to evaluate the bioequivalence of two fixed dose combination (FDC) products of two manufacturers containing nitazoxanide 500 mg and ofloxacin 200 mg in healthy Indian male volunteers. Methods: 24 healthy male volunteers (age 25 +/- 4.6 years; weight 74.5 +/- 7.87 kg) were enrolled in this study. Each subject received a Test fixed dose combination and a Reference fixed dose combination formulation in a randomized, single dose, fasting state, two period, crossover study design with a 1-week washout period between the doses. Extraction of the drugs from the plasma was carried out by precipitation method. Analysis of tizoxanide (active metabolite of nitazoxanide) and ofloxacin from plasma samples was done by a simple and sensitive HPLC method using IN detection developed in our laboratory. An analysis of variance was performed on the pharmacokinetic parameters C-max, AUC(0-t), AUC(0-infinity) using general linear model (GLM) procedures in which sources of variation were subject, formulation, period. Results. The results of this investigation indicated that there were no statistically significant differences between the two products in either the mean concentration-time profiles or in the obtained pharmacokinetic parameters. 90% confidence limits for the log-transformed data of C-max, AUC(0-t), AUC(0-infinity). were within the acceptable range of 0.80-1.25. Conclusion: Thus, these findings clearly indicate that the two products are bioequivalent in terms of rate and extent of drug absorption. Both the preparations were well tolerated with no adverse reactions seen throughout the study.
引用
收藏
页码:679 / 683
页数:5
相关论文
共 50 条
  • [21] Bioequivalence study of fixed pose combination of atorvastatin and ezetimibe tablet in healthy volunteers by LC-MS/MS method
    Gowda, K. Veeran
    Rajan, D. Senthil
    Mandal, U.
    Solomon, W. D. Sam
    Selvan, P. Senthamil
    Bose, A.
    Sarkar, A. K.
    Chattaraj, T. K.
    Pal, T. K.
    ASIAN JOURNAL OF CHEMISTRY, 2007, 19 (02) : 1293 - 1300
  • [22] A randomized Phase I bioequivalence clinical trial of a paediatric fixed-dose combination antiretroviral reconstitutable suspension in healthy adult volunteers
    Esseku, Fredrick
    Joshi, Anjali
    Oyegbile, Yemisi
    Edowhorhu, Grace
    Gbadero, Daniel
    Adeyeye, Moji
    ANTIVIRAL THERAPY, 2013, 18 (02) : 205 - 212
  • [23] Bioequivalence Evaluation of a Fixed Dose Combination Lamivudine plus Stavudine Tablet with Concurrent Administration of Lamivudine Tablet and Stavudine Capsule in Healthy Volunteers
    Chachad, Siddarth
    Lulla, Amar
    Malhotra, Geena
    Purandare, Shrinivas
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2009, 59 (10): : 537 - 540
  • [24] Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products
    Yvonne Schnaars
    Sumedh Gaikwad
    Ulrike Gottwald-Hostalek
    Wolfgang Uhl
    Olga Ribot
    Kanthikiran V. S. Varanasi
    Laura Rodríguez
    Javier Torrejón
    Luis Gómez
    Diabetes Therapy, 2023, 14 : 347 - 362
  • [25] Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers
    Abhyankar, Dhiraj
    Shedage, Ashish
    Gole, Milind
    Raut, Preeti
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2017, 32 (06): : 360 - 366
  • [26] A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition
    Cheah, Kit Yee
    Mah, Kar Yee
    Pang, Lai Hui
    Ng, Shi Min
    Wong, Jia Woei
    Tan, Siew Siew
    Tan, Hong Zhe
    Yuen, Kah Hay
    BMC PHARMACOLOGY & TOXICOLOGY, 2020, 21 (01):
  • [27] A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition
    Kit Yee Cheah
    Kar Yee Mah
    Lai Hui Pang
    Shi Min Ng
    Jia Woei Wong
    Siew Siew Tan
    Hong Zhe Tan
    Kah Hay Yuen
    BMC Pharmacology and Toxicology, 21
  • [28] Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin-Metformin Fixed-Dose Combination Compared with the Originator Products
    Schnaars, Yvonne
    Gaikwad, Sumedh
    Gottwald-Hostalek, Ulrike
    Uhl, Wolfgang
    Ribot, Olga
    Varanasi, Kanthikiran V. S.
    Rodriguez, Laura
    Torrejon, Javier
    Gomez, Luis
    DIABETES THERAPY, 2023, 14 (02) : 347 - 362
  • [29] Bioequivalence Study of Two Different Dapagliflozin Tablet Formulations in Healthy Adult Indian Volunteers
    Kalra, Sanjay
    Bhattacharya, Supratik
    JOURNAL OF DIABETOLOGY, 2022, 13 (03) : 235 - 241
  • [30] Bioequivalence Study Of A Fixed-Dose Combination Tablet Containing Melitracen 10 mg And Flupentixol 0.5 mg In Healthy Chinese Volunteers Under Fasted And Fed Conditions
    Wu, Lihua
    Xu, Chang
    Wu, Guolan
    Zhou, Huili
    Lv, Duo
    Zhai, You
    Huang, Yujie
    Tang, Wenling
    Li, Fangqiong
    Shentu, Jianzhong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 3331 - 3342